05/16/2022

Meet with NETRIS Pharma at the Bio International Convention in San Diego CA (June 13-16 2022)

Reading : 2 min

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering dependence receptors-based drug discovery and development, is confirming today that CEO and Founder Patrick Mehlen, and CFO Christophe Guichard, will be attending the Bio International Convention taking place June 13-16, 2022, in San Diego, CA. Meet with us at the Partnering booth !

For any information, please send an email to  christopheguichard@netrispharma.com

Suggested articles

logo1
12/19/2023

NETRIS Pharma extends Series A to €24.4 million and reinforces its leadership team and Board of Directors

NETRIS Pharma extends Series A to €24.4 million with €7.5 million equity injection Proceeds to enable the completion of 5 ongoing phase 2 clinical studies Reinforces its leadership team and Board of Directors

Reading : 5 min
logo Nature article
08/26/2023

Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor

Reading : 10 min
logo Nature article
08/30/2023

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min